BY OUR PLATFORMS
BY THERAPEUTIC AREA
04 August 2022
Leading scientists from Amsterdam University, Taros Chemicals and Zeclinics have combined expertise and state of the art technologies, to develop an innovative drug discovery platform and accelerate the discovery of new therapies in the field of cardiomyopathies and heart failure.
The project was funded by the prestigious EUREKA-EUROSTARS innovation program to respond to unmet medical needs for directed therapies in the field of cardiomyopathies. Diderick Kuster and Carol Ann Remme from Amsterdam University have successfully setup an in vitro drug screening platform and generated new models of hypertrophic and dilated cardiomyopathy in human iPSC cardiomyocytes. Specific mutations in the troponin gene are known to be associated with cardiomyopathies and the introduction of point mutations in this gene, with CRISPR-Cas9 based genome editing technology, allowed to mimics human clinical HCM and DCM phenotypes such as severe defects in cardiac function and contraction-relaxation in vitro.
The in vitro cardiomyopathy drug screening platform was launched in June 2022 and large-scale screening of compounds will:
The development and launching of the hiPSC cardiomyocyte drug screening platform by the CARDIOMYO consortium, sets the first milestones in the creation of new solutions to fight drug attrition in the field of cardiomyopathies.